BBNXBeta Bionics, Inc.
Beta Bionics, Inc. (BBNX) develops diabetes management technology, including its iLet bionic pancreas. The next catalyst is October 27, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to sustain revenue growth and manage its widening losses.
- Revenue grew 53.9% YoY to $110.13M, but net income remains -$76.38M, with a net margin of -69.4%.
- Free cash flow (TTM) is -$147.45M, and shareholders’ equity stands at $287.61M.
- The company is testing its ability to scale and turn a profit as it faces intense competition in a crowded market.
The Read
Historically, BBNX’s product launches, including the July 1 event, have triggered a median absolute stock move of about 15%.
The schedule
- Tue27Oct
The earnings release will test whether Beta Bionics can deliver stronger-than-expected revenue and margin guidance, which would signal improved commercial execution and product mix. This differs from the last print, which saw a sharp decline due to weak guidance and margin compression.
- Tue3Nov
The shareholder deadline for leadership role in Beta Bionics will test whether the company can secure key leadership positions, which could impact its strategic direction and investor confidence. This event will also test the company's ability to navigate shareholder pressures.
- Tue15Dec
The securities litigation and regulatory investigation will test the company's ability to manage legal and regulatory risks, which could impact its financial performance and investor confidence. This event will also test the company's transparency and compliance efforts.
- Tue12Jan
The FDA warning letter remediation and reinspection update will test the company's ability to address regulatory concerns and improve its compliance processes. This event will also test the company's ability to maintain product quality and regulatory standing.
- Tue9Feb
This release will test the company's ability to sustain revenue growth and improve margins, particularly in light of recent regulatory challenges. The outcome will depend on whether the company can demonstrate progress in product commercialization and cost control.
- Tue20Apr
The Q1 2027 earnings will test the company's ability to maintain momentum in product launches and revenue growth. The outcome will depend on whether the company can demonstrate consistent performance and improved operational efficiency.
- Tue27Jul
This release will test the company's ability to sustain revenue growth and improve margins, particularly in light of recent regulatory challenges. The outcome will depend on whether the company can demonstrate progress in product commercialization and cost control.
Past
- Mon17Aug
Actual outcome: Bull · $20.01 at outcome
Despite the anticipated dilutive secondary equity offering, Beta Bionics shares rallied 14% and exceeded the bull target. The upward momentum was driven by positive analyst coverage from William Blair, which highlighted the company's strategic initiatives to expand into faster-growing segments of the insulin pump market, overshadowing near-term dilution concerns.
Expected capital raise to fund operations and product pipeline due to short cash runway.
- Tue28Jul
Actual outcome: Bear · $14.27 at outcome
Beta Bionics reported a Q2 loss of $0.49 per share, meeting estimates, alongside a 38% year-over-year revenue increase to $32 million driven by new patient starts for its iLet system. Despite the strong top-line growth, the stock fell 9.7% and breached the bear floor, likely pressured by the widening year-over-year net loss and the announcement of a shareholder investigation into potential securities law violations.
Quarterly earnings report focusing on iLet bionic pancreas adoption and cash burn rate.
- Wed1Jul
Actual outcome: Bull · $16.17 at outcome
Despite the announcement of a law firm investigation into potential securities law violations, BBNX shares remained resilient and exceeded the $15.20 bull target. The absence of any negative impact from expected competitor data releases allowed the stock to maintain its momentum and close at $17.00.
Expected competitive data release from major automated insulin delivery peers, challenging BBNX's iLet momentum.
- Tue21Apr
Actual outcome: Bear · $10.08 at outcome
Beta Bionics reported in-line Q1 EPS but missed revenue estimates, which overshadowed the company's decision to raise its full-year 2026 guidance. The top-line miss, combined with lingering investor concerns over a recently announced securities fraud investigation, drove a sharp 17.8% decline in the stock price following the event.
Q1 2026 earnings around $11.2 with an update on iLet adoption, margins, and any commentary on regulatory remediation and legal exposure.
- Wed15Apr
Actual outcome: Bull · $12.20 at outcome
Beta Bionics raised its full-year 2026 guidance and reported a narrower-than-expected Q1 loss, signaling that the iLet bionic pancreas is gaining commercial traction following the reimbursement updates. This improved outlook drove the stock to exceed the $11.20 bull target by the outcome date, as the market prioritized the positive forward-looking guidance over a slight revenue miss and news of a legal investigation.
Major commercial payer coverage and reimbursement decisions for the iLet bionic pancreas around $9.95, which could expand eligible patient populations or leave access constrained.
- Tue24Feb
Actual outcome: Bear · $11.57 at outcome
Beta Bionics reported Q4 EPS that met consensus estimates at -$0.30, but the stock fell 13.6% and broke well below the $13.50 bear floor. The earnings results and forward outlook were completely overshadowed by mounting securities fraud investigations stemming from a massive stock drop earlier in the year. These legal concerns severely damaged investor confidence, driving the bearish outcome despite the company's earlier preliminary revenue beat.
The company previously announced preliminary Q4 revenue of at least $32 million, a strong beat over consensus, indicating accelerating commercial adoption of the iLet Bionic Pancreas. The focus shifts to full-year 2026 guidance and commentary on cash runway and gross margin expansion.
